Acute Decompensated HF Flashcards

1
Q

Acute HF Syndromes

A
  • Acute Myocardial infarction
  • Acute valvular disease
  • Fulminated myocarditis
  • Acute on chronic diastolic heart failure
  • Acute on chronic systolic heart failure
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

Acute on chronic systolic heart failure or ADHF Key Precipitants

A
• Non-compliance
• Poorly controlled HTN
• Ischemia/ACS
• Afib or other arrhythmias 
• Infections
• Pulmonary emboli
• Worsening renal function
-can be from HF meds or OTC
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

Hemodynamic Descriptors of ADHF

A

• Elevated cardiac filling pressures
(congestion)

• Reduction in cardiac output

Thus: Cold and Wet

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

Physical Exam Findings

A
  1. Elevated cardiac filling pressures:
    -Rales
    -JVP, hepatojugular reflux
    -Hepatomegaly
    -Ascites
    -Edema
  2. Low cardiac output:
    - Narrow pulse pressure (PP
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

Goals of Therapy in ADHF

A

Fundamental GOAL: restore and maintain optimal filling pressures on diuretics and vasodilators!

• Relieve symptoms 
-deal w/elevated filling pressures!
-thus diuretics and vasodilators
• Optimize volume status
• Identify etiology
• Identify precipitating factors
• Optimize chronic oral therapy 
• Minimize side effects
• Educate patient/family
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

Current Tx for ADHF

A
  1. Diuretics-reduce volume
  2. Vasodilators-decrease preload and/or afterload
  3. Inotropes
    - augment contractility
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

Diuretics in HF

A
  • IV loop diuretics are mainstay of therapy for acute heart failure (given to ~ 90% of pts)
  • Relieve symptoms of dyspnea and edema in most patients

• Associated with variety of potential problems:
-Electrolyte abnormalities
• wasting of K+, Na+, etc. can set you up for arrhythmias

  • Activation of RAAS and SNS
  • Diuretic resistance
  • Worsening renal function
  • Increased mortality?

*Loops won’t make it to the loop in pts w/renal issues because low RBF. Need higher dose

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

Diuretic Strategies in Patients with ADHF

A

Pts have decreased maximal response to diuretics and take higher doses to achieve same effect as normal

*higher doses are more effective but may cause worsening renal function

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

Tx of Warm and Wet Pt:

A
  1. Enhanced diuresis
    - IV Loop diuretics (furosemide, bumetanide)
  2. Not needed in most, but Some patients maybe IV vasodialtor leading to acute reductions in cardiac filling pressure
    - venous: decrease preload
    - arterial: afterload reduction
  3. Usually don’t need to stimulate contractility to get diuresis
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

Tx of Cold and Wet

A
  1. Warm up before drying out
    - IV vasodilator to decrease SVR to increase CO so that diuretics can actually get to loop (increase RBF)
  2. IV Loop diuretics
  3. IV vasodilators
    - main pro: reduction in mitral regurgitant flow
    - MR can take up to 75% of EF!
  4. Some may need to stimulate cardiac contractility (dobutamine, milrinone, DA)
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

Cold and Dry

A
  1. Assess for filling pressures that would actually make the patient cold and wet
  2. If PCWP less than 12 or RAP less than 5mmHg
    - cautious fluid replacement orally
  3. Limited Options
  4. Positive Inotropes may help temporarily
  5. BB may eventually help, but most can’t tolerate BB b/c limited contractile reserve
  6. Vasodilators may increase CO but probably just cause hypotension
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

IV Vasodilators:

A

Physiologic Rationale:
• Reduce preload (venodilation) and afterload (arterial dilation)

  • Decrease mitral regurgitation (systemic vasodilation)
  • Improve systemic cardiac output, tissue perfusion
  • Decrease left atrial pressure, secondary pulmonary HTN
  • Reduces RV afterload, decreases tricuspid regurgitation
  • Decreases RA pressure
  • IV administration allows for titration
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

Nitroglycerin

A
  • Primarily a venodilator at lower doses (preload reduction)
  • Rapid decline of pulmonary venous and LV filling pressures
  • Reduction in dyspnea
  • Decrease in myocardial O2 consumption
  • Arterial dilator at higher doses
  • Tolerance, headaches
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

Nitroprusside

A
  • Powerful arterial and venous dilator
  • Acts through its active metabolite nitric oxide
  • Very short half-life (~2 min), rapid onset and offset of action

• Arterial vasodilation primarily at level of resistance vessels

• Coronary steal, hypoxemia
–kind of a paradox, but what happens is that vasodilation happens and blood goes to those that were dilated and not to the somewhat dz’d arteries

• Cyanide toxicity, particularly if renal function impaired

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

Nesiritide

A

• Recombinant form of brain natriuretic peptide
• Balanced vasodilator
• Increases cardiac output independent of changes in contractility
– because it reduces afterload
• Weak natriuretic, diuretic
• Longer half-life, risk of prolonged hypotension

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

Summary of Vasodilators

A

• No evidence that in-hospital implementation reduces key outcomes
i.e. recurrent CHF hospitalization or death (ASCEND-HF)

  • Effectively reduce cardiac filling pressures
  • Provide immediate symptomatic relief

• Oral options available for transition
ACE-I, ARBs, hydralazine, nitrates

• Ideal patient: high filling pressures, nl BP or HTN

  • warm & wet, cold & wet
  • risk of hypotension in the cold & dry patient
17
Q

IV Inotrope

A
Physiologic Rationale
• Increases myocardial contractility
• Reduces afterload (vasodilator properties) 
• Decreases end-systolic volume
• Decreases cardiac filling pressures
• Improves end-organ perfusion
18
Q

Dobutamine

A
  • Nonselective beta-1 and beta-2 adrenergic receptor agonist
  • Variable activity on the alpha-1 receptor
  • Low dose: beta-1 and beta-2 prevalent:
  • positive inotropic, lusitropic, chronotropic action
  • vasorelaxation via beta-2 stimulation
  • increased stroke volume, HR

• High dose: alpha-1 activation more evident venous and arterial constriction

19
Q

Milrinone

A
  • Potent phosphodiesterase inhibitor
  • Increases cAMP by preventing its degradation
  • c-AMP activates protein kinase A which phosphorylates key calcium regulatory proteins
  • Enhances inotropy, lusitropy
  • Powerful pulmonary and systemic arterial dilator
  • Effective even if beta-receptor is occupied
  • Should improve RBF and diuretic effectiveness
20
Q

Dopamine

  1. Low Dose
  2. Intermediate
  3. High
A
  1. Low dose: less than 2 mcg
    • vascular D1 activation-coronary, renal, mesenteric beds
    • vasodilation and natriuresis
  2. Intermediate dose (2 to 5 mcg/kg/min):
    • myocardial beta-1 activation
    • positive inotrope, increases SBP, HR
    • No or minor changes in DBP, SVR
  3. High doses (5 to 15 mcg/kg/min):
    • beta-1, alpha-1 agonism
    • vasoconstriction
21
Q

Risks of Inotropes

A
  • **not for most HF (warm and wet)
  • ***Only use for those w/low end-organ perfusion and are in cardiogenic shock

Risks:

  • Arrhythmias, atrial and ventricular
  • Tachycardia
  • Increase myocardial oxygen demand
  • Myocardial infraction
  • Apoptosis
  • Death
22
Q

When yo use Inotropes?

A

Inotropes are NOT routinely used to treat patients with ADHF

Indications:
• Cardiogenic shock with impaired organ function
• Possibly cold&wet,c old&drypatients
• Bridge-to-Transplant or Bridge-to-Device
• Palliation

23
Q

Cardiorenal Syndrome

A

Worsening renal function occurs in 25% of ADHF patients
• defined by a bump in creatinine >0.3 mg/dL
• prolonged hospital stays, higher 60d mortality

Pathophysiology not fully defined
• not easily explained by excessive diuresis
• linked w/ high JVP, RV failure, high intra-abdominal pressure
• effective reduction in JVP, intra-abdominal pressure improves renal function.

*May be just due to “congested” kidney

Tx: inotropes to improve RBF and increaseing response to diuretics, but not always effective

*May need to stop ACE-Is

24
Q

Possible Indications for PA Catheter

A
  • Severe symptoms disproportionate to exam
  • Define right-to-left filling relationship
  • PHTN: pre-capillary vs. post-capillary
  • Life threatening organ dysfunction
  • Pharmacologic optimization
  • Refractoriness to therapy

• Assessment for advanced HF therapies
-Heart transplant, LVAD

25
Q

Discharge Criteria

A

• Clinical Status Goals
Achievement dry weight
Walk without dyspnea, dizziness

• Stability Goals:

24 hours without change meds

> 48 hours off inotropes
• because taking them off sometimes causes renal issues

Renal function stable or improving

***Discharge criteria:
-24 hrs of stable
-fluid status
-blood pressure
-renal function
…..on the oral home regimen

26
Q

Home maintenance program

A

• Education (patient, family)
Dietary sodium restriction
Fluid limitation
Med indications, schedule Instructions for calling office Exercise prescription

  • Flexible diuretic plan
  • Telephone follow-up in 3 days
  • Follow-up clinic appointment in 7-10 days
27
Q

Mechanical Options for Hemodynamic Support

A
  1. Intraaortic balloon pump
  2. Left Ventricular Assist Device
    - connected to the heart and worn and patient can be fully mobile
  3. PVAD
    - percutaneous ventricular assist device
    - small mechanical pump that gives short-term support for the heart from a few hours up to 15 days